Ablynx N.V.

Japan has given the first approval anywhere globally to Daiichi Sankyo Co., Ltd. ’s dual inhibitor of EZH1 (enhancer of zeste homolog 1) and EZH2 Ezharmia (valemetostat; DS-3201), for the treatment o

Sanofi 's approach to drug discovery and early pipeline development has been changing over the last five years, and global head of research and chief scientific officer Frank Nestle said in an intervi

Who: Sanofi and Skyhawk Therapeutics, Inc. What: The two companies have signed an exclusive worldwide partnership to discover and develop small molecule drugs in immunology and oncology using Skyha

The number of biopharmaceutical companies raising venture capital this year has far outpaced the number raising money in public offerings, with 126 venture rounds during the first quarter versus just